Skip to main content

Table 1 Baseline characteristics of studies reporting on incidence of resistance

From: Systematic review of influenza resistance to the neuraminidase inhibitors

  

Study

Intervention

Patients

Study first author

Recruitment

Period

Design*

Quality score**

Purpose

Dose

Duration

Immunostatus

In/ Out

Age group

Zanamivir studies

Boivin31

1997-1998

RCT

High

Treatment

10 mg td

5 days

Competent

Out

Unclear

Hedrick36

1998-1999

RCT

High

Treatment

10 mg td

5 days

Competent

Out

Children

Ambrozaitis29

1997-2000

RCT

High

Prophylactic

10 mg td

14 days

Competent

In

Adults

Gravenstein32

1997-2000

RCT

High

Prophylactic

10 mg td

14 days

Competent

In

Adults

Hayden(1)34

1999-2000

RCT

High

Prophylactic

10 mg td

10 days

Competent

Out

Adults

Peramivir study

Barosso(a)30

1999-2000

RCT

High

Treatment

100, 200, or 400 mg qd, or 200 md q12 h

5 days

Competent

Out

Adults

Barosso(b)30

1999-2000

RCT

High

Treatment

800 mg qd(day1) then400 mg q24 or 400 mg q24

5 days

Competent

Out

Adults

Barosso(c)30

1999-2000

RCT

High

Treatment

50, 200, or 400 mg qd

5 days

Competent

Out

Adults

Barosso(d)30

1999-2000

RCT

High

Treatment

200, 400 or 800 mg

5 days

Competent

Out

Adults

Oseltamivir studies

Whitley38

1998-1999

RCT

High

Treatment

2 mg/kg twice daily (max 100 mg/day)

5 days

Competent

Out

Children

Hayden(2)35

2000-2001

RCT

High

Prophylactic

75 mg once daily

10 days

Competent

Out

Mix

Hayden(3-a)33

2000

RCT

High

Treatment

75 mg/150 mg once/twice daily

5 days

Competent

Out

Adult

Hayden (3-b)33

2000

RCT

High

Treatment

75 mg once daily

5 days

Competent

Out

Adult

Hayden (3-c)33

2000

RCT

High

Prophylactic

75 mg once daily

7 days

Competent

Out

Adult

Ison37

Before 2009

RCT

High

Prophylactic

75 mg orally or suspension once daily for age = > 13, weight-based or suspension for age < 13

12 days

Compromised

In

Unclear

Kiso15

2002-2003

OBS

6/6

Treatment

4 mg/kg

2-5 days

Competent

Mix

Children

Kawai42

2003-2004

OBS

6/6

Treatment

75 mg twice daily for adults and children > 35 kg, weight-based twice daily for children < 35 kg

5 days

Unclear

Out

Mix

Hatekayama41

2004-2005

OBS

5/6

Treatment

Unclear

Unclear

Mix

Unclear

Children

Stephenson43

2005-2007

OBS

6/6

Treatment

Twice daily weight-based dosing regimen

5 days

Competent

Unclear

Mix

Cost39

2009

OBS

4/6

Prophylactic

Unclear

Unclear

Compromised

In

Children

Harvala40

2009

OBS

6/6

Treatment

Unclear

Unclear

Mix

Unclear

Unclear

Tramontana44

2009

OBS

6/6

Treatment

Varied across patients

Up to 43 days

Compromised

In

Adults

Wang45

2009

OBS

6/6

Treatment

Unclear

Unclear

Mix

In

mix

Winzer46

2009

OBS

5/6

Treatment

Unclear

Unclear

Unclear

Unclear

mix

  1. *Study design is either a randomized clinical trial (RCT) or an observational study (OBS)
  2. **Quality scores for RCTs range from 1 to 4. Study scores for OBSs range from 1 to 6. Low scores indicate low quality, high scores indicate high quality.